BLTE vs. CYTK, SMMT, OGN, BBIO, MDGL, APLS, NUVL, ALPN, ALKS, and CRNX
Should you be buying Belite Bio stock or one of its competitors? The main competitors of Belite Bio include Cytokinetics (CYTK), Summit Therapeutics (SMMT), Organon & Co. (OGN), BridgeBio Pharma (BBIO), Madrigal Pharmaceuticals (MDGL), Apellis Pharmaceuticals (APLS), Nuvalent (NUVL), Alpine Immune Sciences (ALPN), Alkermes (ALKS), and Crinetics Pharmaceuticals (CRNX). These companies are all part of the "pharmaceutical preparations" industry.
Belite Bio (NASDAQ:BLTE) and Cytokinetics (NASDAQ:CYTK) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation, community ranking and profitability.
0.5% of Belite Bio shares are owned by institutional investors. 13.3% of Belite Bio shares are owned by insiders. Comparatively, 3.4% of Cytokinetics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
In the previous week, Cytokinetics had 25 more articles in the media than Belite Bio. MarketBeat recorded 27 mentions for Cytokinetics and 2 mentions for Belite Bio. Belite Bio's average media sentiment score of 1.39 beat Cytokinetics' score of 0.75 indicating that Belite Bio is being referred to more favorably in the media.
Belite Bio has a beta of -1.43, suggesting that its share price is 243% less volatile than the S&P 500. Comparatively, Cytokinetics has a beta of 0.75, suggesting that its share price is 25% less volatile than the S&P 500.
Belite Bio has higher earnings, but lower revenue than Cytokinetics. Belite Bio is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.
Belite Bio has a net margin of 0.00% compared to Cytokinetics' net margin of -14,141.74%. Cytokinetics' return on equity of 0.00% beat Belite Bio's return on equity.
Belite Bio presently has a consensus target price of $44.83, suggesting a potential downside of 6.73%. Cytokinetics has a consensus target price of $76.41, suggesting a potential upside of 44.36%. Given Cytokinetics' higher probable upside, analysts clearly believe Cytokinetics is more favorable than Belite Bio.
Cytokinetics received 759 more outperform votes than Belite Bio when rated by MarketBeat users. However, 95.83% of users gave Belite Bio an outperform vote while only 79.31% of users gave Cytokinetics an outperform vote.
Summary
Belite Bio beats Cytokinetics on 9 of the 17 factors compared between the two stocks.
Get Belite Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for BLTE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BLTE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Belite Bio Competitors List
Related Companies and Tools
